Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.
The company's President and CEO, Marc H. Hedrick, M.D., will engage in a fireside chat with H.C. Wainwright's VP of Equity Research, Sean Lee. The discussion will be available on demand starting September 5, 2025, at 7:00 AM ET for registered conference attendees.
Plus Therapeutics (NASDAQ:PSTV), azienda farmaceutica in fase clinica focalizzata sullo sviluppo di radioterapeutici mirati per i tumori del sistema nervoso centrale (SNC), parteciperà al H.C. Wainwright 27th Annual Global Investment Conference dall'8 al 10 settembre 2025.
Il Presidente e CEO della società, Marc H. Hedrick, M.D., sarà protagonista di una conversazione informale con Sean Lee, VP di Equity Research di H.C. Wainwright. La discussione sarà disponibile on demand a partire dal 5 settembre 2025 alle 7:00 ET per i partecipanti registrati alla conferenza.
Plus Therapeutics (NASDAQ:PSTV), una empresa farmacéutica en fase clínica centrada en desarrollar radiofármacos dirigidos para cánceres del sistema nervioso central (SNC), participará en el H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025.
El presidente y CEO de la compañía, Marc H. Hedrick, M.D., mantendrá una charla junto a la chimenea con Sean Lee, vicepresidente de Equity Research de H.C. Wainwright. La conversación estará disponible bajo demanda a partir del 5 de septiembre de 2025 a las 7:00 ET para los asistentes registrados a la conferencia.
Plus Therapeutics (NASDAQ:PSTV)는 중추신경계(CNS) 암을 표적하는 방사성 치료제 개발에 주력하는 임상 단계 제약사로, H.C. Wainwright 27th Annual Global Investment Conference에 2025년 9월 8일부터 10일까지 참가합니다.
회사의 사장 겸 CEO인 Marc H. Hedrick, M.D.가 H.C. Wainwright의 주식 리서치 부문 부사장인 Sean Lee와 화상 대담을 진행합니다. 이 대담은 등록된 콘퍼런스 참가자를 위해 2025년 9월 5일 오전 7:00 ET부터 온디맨드로 시청할 수 있습니다.
Plus Therapeutics (NASDAQ:PSTV), société pharmaceutique en phase clinique spécialisée dans le développement de radiothérapeutiques ciblées pour les cancers du système nerveux central (SNC), participera à la H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025.
Le président-directeur général de la société, Marc H. Hedrick, M.D., participera à un entretien informel avec Sean Lee, vice-président Equity Research chez H.C. Wainwright. La discussion sera disponible à la demande à partir du 5 septembre 2025 à 7h00 ET pour les participants inscrits à la conférence.
Plus Therapeutics (NASDAQ:PSTV), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung zielgerichteter Radiotherapeutika für Tumoren des zentralen Nervensystems (ZNS) spezialisiert hat, wird an der H.C. Wainwright 27th Annual Global Investment Conference vom 8. bis 10. September 2025 teilnehmen.
Der Präsident und CEO des Unternehmens, Marc H. Hedrick, M.D., wird ein Gespräch am Kamin mit Sean Lee, VP Equity Research bei H.C. Wainwright, führen. Die Diskussion ist für registrierte Konferenzteilnehmer ab dem 5. September 2025 um 7:00 ET auf Abruf verfügbar.
- None.
- None.
HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.
Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer will participate in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright. The fireside chat will be available on demand beginning Friday, September 5 at 7:00am ET for registered investors of the conference. To request a one-on-one meeting with Dr. Hedrick and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.
Investor Contact
CORE IR
investor@plustherapeutics.com
FAQ
When is Plus Therapeutics (PSTV) presenting at the H.C. Wainwright Conference 2025?
Who will represent Plus Therapeutics (PSTV) at the H.C. Wainwright Conference?
What is Plus Therapeutics' (PSTV) main business focus?
How can investors access Plus Therapeutics' (PSTV) presentation at the H.C. Wainwright Conference?
